-
Subject Areas on Research
-
(18)F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors: Value to Patient Management and Survival Outcomes.
-
(18)F-Fluorothymidine PET-CT for resected malignant gliomas before radiotherapy: tumor extent according to proliferative activity compared with MRI.
-
125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
-
2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
-
4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
-
5-[211 At]astato-2'-deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation.
-
A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in Gliomas.
-
A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer.
-
A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
-
A comprehensive outlook on intracerebral therapy of malignant gliomas.
-
A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas?
-
A genetically tractable model of human glioma formation.
-
A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent.
-
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
-
A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure.
-
A machine learning-based prediction model of H3K27M mutations in brainstem gliomas using conventional MRI and clinical features.
-
A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer.
-
A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.
-
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
-
A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma.
-
A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.
-
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
-
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.
-
A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.
-
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
-
A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study.
-
A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.
-
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group.
-
A pial window model for the intracranial study of human glioma microvascular function.
-
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
-
A pooled multisite analysis of the effects of atopic medical conditions in glioma risk in different ethnic groups.
-
A pooled multisite analysis of the effects of female reproductive hormones on glioma risk.
-
A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas.
-
A serially transplantable human giant cell glioblastoma that maintains a near-haploid stem line.
-
A variable age of onset segregation model for linkage analysis, with correction for ascertainment, applied to glioma.
-
AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma.
-
ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis.
-
ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium.
-
AJAP1 is dysregulated at an early stage of gliomagenesis and suppresses invasion through cytoskeleton reorganization.
-
ANZCCSG BabyBrain99; intensified systemic chemotherapy, second look surgery and involved field radiation in young children with central nervous system malignancy.
-
Accelerated Brain DCE-MRI Using Iterative Reconstruction With Total Generalized Variation Penalty for Quantitative Pharmacokinetic Analysis: A Feasibility Study.
-
Acidic stress promotes a glioma stem cell phenotype.
-
Acute leukemia following treatment of malignant glioma.
-
Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities.
-
Adoptive immunotherapy for malignant glioma.
-
Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014.
-
Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.
-
Advances in the treatment of malignant gliomas.
-
Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.
-
Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas.
-
Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011.
-
Alterations of the TP53 gene in human gliomas.
-
Altered expression of ganglioside phenotypes of human gliomas in vivo and in vitro.
-
Altered genetic response to beta-adrenergic receptor activation in late passage C6 glioma cells.
-
Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts.
-
An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
-
An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
-
An improved method of preparing Schmidt-Ruppin Rous sarcoma virus for brain tumor induction in mammals.
-
An investigation of machine learning methods in delta-radiomics feature analysis.
-
Analysis of 60 reported glioma risk SNPs replicates published GWAS findings but fails to replicate associations from published candidate-gene studies.
-
Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells.
-
Angiocentric glioma-like tumor of the midbrain.
-
Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
-
Anti-GM2 monoclonal antibodies induce necrosis in GM2-rich cultures of a human glioma cell line.
-
Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma.
-
Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma.
-
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.
-
Antibody-based immunotherapy for malignant glioma.
-
Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
-
Antigenic heterogeneity of human anaplastic gliomas and glioma-derived cell lines defined by monoclonal antibodies.
-
Antineoplastic activity of boron-containing thymidine nucleosides in Tmolt3 leukemic cells.
-
Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
-
Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
-
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas.
-
Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay.
-
Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.
-
Applications of monoclonal antibodies in the diagnosis and treatment of primary brain tumors.
-
Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study.
-
Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.
-
Aspirin, NSAIDs, and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-analysis.
-
Assessing effects of pressure on tumor and normal tissue physiology using an automated self-calibrated, pressure-sensing probe for diffuse reflectance spectroscopy.
-
Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing.
-
Assessment of type of allergy and antihistamine use in the development of glioma.
-
Association and interactions between DNA repair gene polymorphisms and adult glioma.
-
Association between glioma and history of allergies, asthma, and eczema: a case-control study with three groups of controls.
-
Association of genomic subtypes of lower-grade gliomas with shape features automatically extracted by a deep learning algorithm.
-
Association of sequence variants on chromosomes 20, 11, and 5 (20q13.33, 11q23.3, and 5p15.33) with glioma susceptibility in a Chinese population.
-
Attenuation of herpes simplex virus neurovirulence with picornavirus cis-acting genetic elements.
-
Avastin: more questions than answers. .
-
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
-
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial.
-
BCR-NTRK2 fusion in a low-grade glioma with distinctive morphology and unexpected aggressive behavior.
-
Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
-
Bevacizumab for the treatment of high-grade glioma.
-
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
-
Bevacizumab: radiation combination produces restricted diffusion on brain MRI.
-
Binding of tenascin-C to soluble fibronectin and matrix fibrils.
-
Biochemical and structural studies of tenascin/hexabrachion proteins.
-
Biological Role and Therapeutic Potential of IDH Mutations in Cancer.
-
Biology of gliomas: potential clinical implications of glioma cellular heterogeneity.
-
Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma.
-
Brain cancer stem cells display preferential sensitivity to Akt inhibition.
-
Brain stem gliomas: patterns of care in Victoria from 1998-2000.
-
Brain tumor types induced by the Schmidt-Ruppin strain of Rous sarcoma virus in inbred Fischer rats.
-
Brain tumors induced in dogs by the Schmidt-Ruppin strain of Rous sarcoma virus. Neuropathological and immunological observations.
-
Bromodeoxyuridine-mediated radiosensitization in human glioma: the effect of concentration, duration, and fluoropyrimidine modulation.
-
Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
-
Buthionine sulfoximine-mediated depletion of glutathione in intracranial human glioma-derived xenografts.
-
CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the Limitations.
-
Cancer immunoediting in malignant glioma.
-
Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability.
-
Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study.
-
Caspase-8 levels affect necessity for mitochondrial amplification in death ligand-induced glioma cell apoptosis.
-
Catabolism of radioiodinated murine monoclonal antibody F(ab')2 fragment labeled using N-succinimidyl 3-iodobenzoate and Iodogen methods.
-
Cell adhesion to fibronectin and tenascin: quantitative measurements of initial binding and subsequent strengthening response.
-
Cell adhesion to fibronectin and tenascin: quantitative measurements of initial binding and subsequent strengthening response.
-
Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C.
-
Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.
-
Cell-type-specific repression of internal ribosome entry site activity by double-stranded RNA-binding protein 76.
-
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
-
Cerebral blood flow, blood volume, and vascular permeability of cerebral glioma assessed with dynamic CT perfusion imaging.
-
Cerebral physiology in dogs after brain-tumor induction with Schmidt-Ruppin Rous sarcoma virus: experiences with radioiodinated normal and antiviral immunoglobulin G.
-
Cerebrovascular reactivity mapping in patients with low grade gliomas undergoing presurgical sensorimotor mapping with BOLD fMRI.
-
Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study.
-
Changes in gamma-aminobutyric acid and somatostatin in epileptic cortex associated with low-grade gliomas.
-
Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry.
-
Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.
-
Characterization of three restricted specificity monoclonal antibodies raised against the human glioma cell line D-54 MG.
-
Chemical structure of carbamoylating groups and their relationship to bone marrow toxicity and antiglioma activity of bifunctionally alkylating and carbamoylating nitrosoureas.
-
Chemotherapy and novel therapeutic approaches in malignant glioma.
-
Chemotherapy for adults with malignant glioma.
-
Chemotherapy is useful in the treatment of gliomas. Discussant.
-
Chemotherapy of brain tumors.
-
Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology.
-
Chimeric anti-tenascin antibody 81C6: increased tumor localization compared with its murine parent.
-
Chordoid glioma: a case report and molecular characterization of five cases.
-
Chromosomal composition of four permanent cultured cell lines derived from human gliomas.
-
Chromosomal composition of malignant human gliomas through serial subcutaneous transplantation in athymic mice.
-
Chromosomal progression of malignant human gliomas from biopsy to establishment as permanent lines in vitro.
-
Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25.
-
Clinical immunotherapy for brain tumors.
-
Clinical trial end points for high-grade glioma: the evolving landscape.
-
Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.
-
Combating immunosuppression in glioma.
-
Combination chemotherapy in vitro exploiting glutamine metabolism of human glioma and medulloblastoma.
-
Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
-
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.
-
Combining diffusion and perfusion differentiates tumor from bevacizumab-related imaging abnormality (bria).
-
Commentary: A Neurosurgeon's Guide to Cognitive Dysfunction in Adult Glioma.
-
Commentary: Optimizing Postoperative Surveillance of Pediatric Low-Grade Glioma Using Tumor Behavior Patterns.
-
Comparative localization of glioma-reactive monoclonal antibodies in vivo in an athymic mouse human glioma xenograft model.
-
Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts.
-
Comparative permeability of different glioma models to horseradish peroxidase.
-
Comparison of fluctuations of oxygen tension in FSA, 9L, and R3230AC tumors in rats.
-
Comparison of intensity-modulated tomotherapy with stereotactically guided conformal radiotherapy for brain tumors.
-
Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration.
-
Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging.
-
Comparison of serial PET and MRI scans in a pediatric patient with a brainstem glioma.
-
Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging.
-
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
-
Concurrent measurements of blood flow and transcapillary transport in xenotransplanted human gliomas in immunosuppressed rats.
-
Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.
-
Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas.
-
Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.
-
Continuous human glioma-derived cell lines UC-11MG and UC-302MG. Morphologic, immunocytochemical and chromosomal characterization.
-
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
-
Correlation of 1p-19q-defects in human gliomas with the light microscopic appearance of oligodendroglioma.
-
Correlation of neuropathologic findings, computerized tomographic and high-resolution ultrasound scans of canine avian sarcoma virus-induced brain tumors.
-
Cortical localization of temporal lobe language sites in patients with gliomas.
-
Craniotomy for tumor treatment in an intraoperative magnetic resonance imaging unit.
-
Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor.
-
Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma.
-
Cryptococcal meningitis in patients with glioma: a report of two cases.
-
Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.
-
Cytopathologic characteristics of permanent cell lines derived from anaplastic human gliomas.
-
Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells.
-
DNA content and chromosomes in permanent cultured cell lines derived from malignant human gliomas.
-
DNA methyltransferase levels and altered CpG methylation in the total genome and in the GSTP1 gene in human glioma cells transfected with sense and antisense DNA methyltransferase cDNA.
-
Daily intake of antioxidants in relation to survival among adult patients diagnosed with malignant glioma.
-
Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.
-
Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function.
-
Deletions and rearrangements inactivate the p16INK4 gene in human glioma cells.
-
Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies.
-
Description of selected characteristics of familial glioma patients - results from the Gliogene Consortium.
-
Detecting treatment-by-centre interaction in multi-centre clinical trials.
-
Detection of glioma-associated gangliosides GM2, GD2, GD3, 3'-isoLM1 3',6'-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies.
-
Development of novel targeted therapies in the treatment of malignant glioma.
-
Developmental anomalies of the skin.
-
Diet and risk of glioma: targets for prevention remain elusive.
-
Differential expression of ros oncogene in primary human astrocytomas and astrocytoma cell lines.
-
Differential retention of rhodamine 123 by avian sarcoma virus-induced glioma and normal brain tissue of the rat in vivo.
-
Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman.
-
Diffuse midline gliomas with subclonal H3F3A K27M mutation and mosaic H3.3 K27M mutant protein expression.
-
Diffuse non-midline glioma with H3F3A K27M mutation: a prognostic and treatment dilemma.
-
Dihydrofolate reductase in primary brain tumors, cell cultures of central nervous system origin, and normal brain during fetal and neonatal growth.
-
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
-
Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas.
-
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
-
Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses.
-
Distinction between cerebral abscesses and high-grade neoplasms by dynamic susceptibility contrast perfusion MRI.
-
Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma.
-
Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions.
-
Distribution of type VI collagen in human gliomas: comparison with fibronectin and glioma-mesenchymal matrix glycoprotein.
-
Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy.
-
Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
-
Dying glioma cells establish a proangiogenic microenvironment through a caspase 3 dependent mechanism.
-
Dynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapies.
-
Dynamics of Circulating γδ T Cell Activity in an Immunocompetent Mouse Model of High-Grade Glioma.
-
EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.
-
Easing the Journey-an Updated Review of Palliative Care for the Patient with High-Grade Glioma.
-
Editorial: Turning fluorescence into black and white.
-
Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro.
-
Effect of glutamate analogues on brain tumor cell lines.
-
Effect of methylprednisolone on radiotherapy of F344 rats with avian sarcoma virus induced gliomas.
-
Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier.
-
Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.
-
Effects of therapy on the 1H NMR spectrum of a human glioma line.
-
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.
-
Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model.
-
Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia.
-
Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles.
-
Enhanced oncolytic virotherapy through oxidative stress inhibition.
-
Enhanced optical imaging of human gliomas and tumor margins.
-
Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyltransferase gene and altered activities of DNA polymerases alpha and beta, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy.
-
Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl)benzoate.
-
Enhanced tumour uptake of radiolabelled antibodies by hyperthermia. Part II: Application of the thermal equivalency equation.
-
Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia.
-
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
-
Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.
-
Epidemiology and Molecular Epidemiology.
-
Epidemiology of Intracranial Gliomas.
-
Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017.
-
Epidemiology of gliomas.
-
Epidermal growth factor receptor and variant III targeted immunotherapy.
-
Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition.
-
Establishment of patient-derived organoid models of lower-grade glioma.
-
Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study.
-
Evaluating changes in radiation treatment volumes from post-operative to same-day planning MRI in High-grade gliomas.
-
Evaluating radiation-induced white matter changes in patients treated with stereotactic radiosurgery using diffusion tensor imaging: a pilot study.
-
Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium.
-
Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.
-
Evaluation of the lipid-soluble diaminopyrimidines, metoprine and etoprine, in the avian sarcoma virus rat glioma model.
-
Evans blue nanocarriers visually demarcate margins of invasive gliomas.
-
Evidence-based Treatment for Low-grade Glioma.
-
Evolving management of low grade glioma: No consensus amongst treating clinicians.
-
Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma.
-
Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.
-
Experience with irinotecan for the treatment of malignant glioma.
-
Experimental allergic encephalomyelitis in Lewis rats bearing avian sarcoma virus-induced brain tumors.
-
Experimental gliomas: an autoradiographic study of the endothelial component.
-
Exploiting metabolic differences in glioma therapy.
-
Exploring the association between melanoma and glioma risks.
-
Expression and mutation analysis of the Wilms' tumor 1 gene in human neural tumors.
-
Expression and regulation of calcium-independent protein kinase C in NG 108-15 cell differentiation.
-
Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.
-
Expression of O6-methylguanine-DNA methyltransferase in malignant human glioma cell lines.
-
Factors controlling oxygen utilization.
-
Factors influencing the cell type of brain tumors induced in dogs by Schmidt-Ruppin Rous sarcoma virus.
-
Familial gliomas: cases in two pairs of brothers.
-
Fibronectin and glial fibrillary acidic protein expression in normal human brain and anaplastic human gliomas.
-
Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study.
-
First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach.
-
Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.
-
Fluorine-18-labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography.
-
Formation and repair of 1,3-bis-(2-chloroethyl)-1-nitrosourea and cisplatin induced total genomic DNA interstrand crosslinks in human glioma cells.
-
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.
-
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
-
GD3 expression by cultured human tumor cells of neuroectodermal origin.
-
GLIOGENE an International Consortium to Understand Familial Glioma.
-
GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody.
-
GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice.
-
Gadopentetate-dimeglumine-enhanced MR imaging of gliomatosis cerebri: appearance mimicking leptomeningeal tumor dissemination.
-
Gamma-radiation sensitivity and polymorphisms in RAD51L1 modulate glioma risk.
-
Gamma-radiation sensitivity and risk of glioma.
-
Gamma-ray mutagen sensitivity and survival in patients with glioma.
-
Gangliosides in the human glioma cell line U-118 MG grown in culture or as xenografts in nude rats.
-
Gene amplification in malignant human gliomas: clinical and histopathologic aspects.
-
General immunocompetence of rats bearing avian sarcoma virus-induced intracranial tumors.
-
Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system.
-
Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity.
-
Genetic polymorphisms in glutathione S-transferase mu and theta, N-acetyltransferase, and CYP1A1 and risk of gliomas.
-
Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis.
-
Genetic variations in the homologous recombination repair pathway genes modify risk of glioma.
-
Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity.
-
Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors.
-
Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the Gliogene Consortium.
-
Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas.
-
Germline cancer predisposition variants and pediatric glioma: a population-based study in California.
-
Germline mutations in shelterin complex genes are associated with familial glioma.
-
Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer.
-
Glial fibrillary acidic protein synthesized in vitro using messenger RNA from a human glioma cell line.
-
Glial-mesenchymal tropism of in vivo avian sarcoma virus neuro-oncogenesis in rats.
-
Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles.
-
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
-
Glioma incidence and survival variations by county-level socioeconomic measures.
-
Glioma progression is shaped by genetic evolution and microenvironment interactions.
-
Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics.
-
Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2.
-
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.
-
Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium.
-
Glioma-associated antigens defined by monoclonal antibodies against an avian sarcoma virus-induced rat astrocytoma.
-
Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study.
-
Gliomas.
-
Gliomatosis cerebri presenting with optic nerve involvement: MRI.
-
Gliomatosis cerebri: cytologic and autopsy findings in a case involving the entire neuraxis.
-
Glutathione S-transferase polymorphisms and survival in primary malignant glioma.
-
Granular presence of terminin is the marker to distinguish between the senescent and quiescent states.
-
Grey matter edema: the marginal zone of autochthonous virally-induced gliomas.
-
Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines.
-
Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines.
-
Growth, morphology, and serial transplantation of anaplastic human gliomas in athymic mice.
-
HIF-miR-215-KDM1B promotes glioma-initiating cell adaptation to hypoxia.
-
Halogenated pyrimidine sensitization of low dose rate irradiation in human malignant glioma.
-
Ham56-immunoreactive macrophages in untreated infiltrating gliomas.
-
Heat shock protein 70-binding protein 1 is highly expressed in high-grade gliomas, interacts with multiple heat shock protein 70 family members, and specifically binds brain tumor cell surfaces.
-
Heterogeneity of Genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas.
-
Hexabrachion proteins in embryonic chicken tissues and human tumors.
-
Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG.
-
History of chickenpox in glioma risk: a report from the glioma international case-control study (GICC).
-
Hitting Gliomas When They Are Down: Exploiting IDH-Mutant Metabolic Vulnerabilities.
-
How heterogeneous are gliomas?
-
Human brain tumor xenografts.
-
Human fetal brain antigen expression common to tumors of neuroectodermal tissue origin.
-
Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody.
-
Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma.
-
Hydroxyurea synchronization increases mitotic yield in human glioma cell lines.
-
Hyperimmunization of non-human primates with BCG-CW and cultured human glioma-derived cells. Production of reactive antisera and absence of EAE induction.
-
Hyperthermic modulation of radiolabelled antibody uptake in a human glioma xenograft and normal tissues.
-
IDH1 and IDH2 hotspot mutations are not found in canine glioma.
-
IDH1 and IDH2 mutations in gliomas.
-
INTRACRANIAL TUMORS IN INFANCY AND CHILDHOOD. A CLINICAL STUDY OF TWENTY CASES.
-
Identification of a brain- and reproductive-organs-specific gene responsive to DNA damage and retinoic acid.
-
Identification of an amplified, highly expressed gene in a human glioma.
-
Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography.
-
Identification of resting cells by dual-parameter flow cytometry of statin expression and DNA content.
-
IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.
-
Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
-
Immune Checkpoint Inhibitors in Gliomas.
-
Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas.
-
Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy.
-
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
-
Immune suppression in gliomas.
-
Immunobiologic aspects of the brain and human gliomas. A review.
-
Immunobiology of human gliomas.
-
Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients.
-
Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study.
-
Immunobiology of primary intracranial tumors. Part 8: Serological responses to active immunization of patients with anaplastic gliomas.
-
Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein.
-
Immunohistochemical detection of factor VIII/von Willebrand factor in hyperplastic endothelial cells in glioblastoma multiforme and mixed glioma-sarcoma.
-
Immunohistochemical study of glial fibrillary acidic protein in avian sarcoma virus-induced gliomas in dogs.
-
Immunolocalization of laminin in neoplasms of the central and peripheral nervous systems.
-
Immunolocalization of monoclonal antibody-defined extracellular matrix antigens in human brain tumors.
-
Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines.
-
Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
-
Immunotherapy approaches for malignant glioma from 2007 to 2009.
-
Immunotherapy approaches in the treatment of malignant brain tumors.
-
Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
-
Impact of atopy on risk of glioma: a Mendelian randomisation study.
-
Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients.
-
Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas.
-
Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate.
-
Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate.
-
In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter.
-
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
-
In vivo BOLD contrast MRI mapping of subcutaneous vascular function and maturation: validation by intravital microscopy.
-
In vivo growth conditions suppress the expression of ganglioside GM2 and favour that of lacto series gangliosides in the human glioma D-54MG cell line.
-
In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies.
-
In vivo quantitation of regional cerebral blood flow in glioma and cerebral infarction: validation of the HIPDm-SPECT method.
-
Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma.
-
Incidence patterns for primary malignant spinal cord gliomas: a Surveillance, Epidemiology, and End Results study.
-
Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv.
-
Increased chromosomal instability in peripheral lymphocytes and risk of human gliomas.
-
Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.
-
Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion.
-
Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin.
-
Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells.
-
Influence of age at inoculation on avian oncornavirus-induced brain tumor incidence, tumor morphology, and postinoculation survival in F344 rats.
-
Influence of glutamine on the growth of human glioma and medulloblastoma in culture.
-
Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.
-
Influence of obesity-related risk factors in the aetiology of glioma.
-
Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology.
-
Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program.
-
Initial testing of cisplatin by the pediatric preclinical testing program.
-
Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma.
-
Insulin-like growth factor I induces tumor hexokinase RNA expression in cancer cells.
-
Intergeneric poliovirus recombinants for the treatment of malignant glioma.
-
International Differences in Treatment and Clinical Outcomes for High Grade Glioma.
-
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.
-
Interstitial flow in a 3D microenvironment increases glioma invasion by a CXCR4-dependent mechanism.
-
Interstitial hyperthermia and iridium brachytherapy in treatment of malignant glioma. A phase I clinical trial.
-
Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats.
-
Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide.
-
Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.
-
Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum.
-
Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning.
-
Intracerebral transplantation of a human glioma line in immunosuppressed rats.
-
Intraoperative mapping during repeat awake craniotomy reveals the functional plasticity of adult cortex.
-
Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats.
-
Intravenous adenosine selectively increases blood flow to xenotransplanted intracerebral gliomas.
-
Introduction.
-
Invasiveness of human glioma cell lines in vitro: relation to tumorigenicity in athymic mice.
-
Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas.
-
Iodine-125 interstitial irradiation of virally induced dog brain tumours.
-
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
-
Irinotecan therapy in adults with recurrent or progressive malignant glioma.
-
Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
-
Irinotecan: promising activity in the treatment of malignant glioma.
-
Is mortality due to primary malignant brain and other central nervous system tumors decreasing?
-
Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
-
Isocitrate dehydrogenase mutations in gliomas.
-
Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.
-
Isolation of Glioma-Initiating Cells for Biological Study.
-
Kinetics and glial fibrillary acidic (GFA) protein production in a transplantable human giant cell glioblastoma (D-212 MG) of near haploid karyotype maintained in an organ culture system. An immunohistochemistry study.
-
L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma.
-
L-buthionine-sulfoximine-mediated radiosensitization in experimental interstitial radiotherapy of intracerebral D-54 MG glioma xenografts in athymic mice.
-
Labeling Monoclonal Antibody with α-emitting 211At at High Activity Levels via a Tin Precursor.
-
Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.
-
Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.
-
Lack of association between modifiable exposures and glioma risk: a Mendelian randomization analysis.
-
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.
-
Language outcomes after resection of dominant inferior parietal lobule gliomas.
-
Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study.
-
Leptin and its receptor are overexpressed in brain tumors and correlate with the degree of malignancy.
-
Local delivery methods of therapeutic agents in the treatment of diffuse intrinsic brainstem gliomas.
-
Local production of TGF beta1 inhibits cerebral edema, enhances TNF-alpha induced apoptosis and improves survival in a murine glioma model.
-
Localization of fluorine-18-labeled Mel-14 monoclonal antibody F(ab')2 fragment in a subcutaneous xenograft model.
-
Long telomeres in need of a SNP: Germline contributions of telomere maintenance to glioma.
-
Long term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy. Clinical characteristics and treatment related toxicities. The Pediatric Oncology Group.
-
Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?
-
Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk.
-
Longitudinal molecular trajectories of diffuse glioma in adults.
-
Loss of heterozygosity for 10q loci in human gliomas.
-
Low tumor mutational burden and immunotherapy in gliomas.
-
Low-grade glioma.
-
Low-grade gliomas associated with intractable epilepsy: seizure outcome utilizing electrocorticography during tumor resection.
-
MIBG inhibits respiration: potential for radio- and hyperthermic sensitization.
-
MR measurement of normal and pathologic brainstem diameters.
-
MRI-guided stereotactic biopsy in the diagnosis of glioma: comparison of biopsy and surgical resection specimen.
-
Machine Learning-Based Multiparametric Magnetic Resonance Imaging Radiomics for Prediction of H3K27M Mutation in Midline Gliomas.
-
Magnetic resonance imaging of optic gliomas.
-
Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.
-
Malignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors.
-
Malignant glioma--timing of response to radiation therapy.
-
Malignant gliomas in older adults with poor prognostic signs. Getting nowhere, and taking a long time to do it.
-
Management of glioma in Victoria (1998-2000): retrospective cohort study.
-
Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
-
Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors.
-
Maximizing the efficacy of angiogenesis inhibitors.
-
Mechanism of anti-glioma activity and in vivo efficacy of the cannabinoid ligand KM-233.
-
Mechanisms of action of rapamycin in gliomas.
-
Medical diagnostic radiation exposures and risk of gliomas.
-
Medulloblastoma cell-substrate interaction in vitro.
-
Mendelian randomisation study of the relationship between vitamin D and risk of glioma.
-
Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis.
-
Met and hepatocyte growth factor/scatter factor expression in human gliomas.
-
Metabolomic profiling of sphingolipids in human glioma cell lines by liquid chromatography tandem mass spectrometry.
-
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.
-
MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B.
-
Microvascular abnormalities in virally-induced canine brain tumors. Structural bases for altered blood-brain barrier function.
-
Minimal and inducible regulation of tissue factor pathway inhibitor-2 in human gliomas.
-
Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.
-
Models of epigenetic age capture patterns of DNA methylation in glioma associated with molecular subtype, survival, and recurrence.
-
Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody.
-
Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate.
-
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.
-
Molecular and clinicopathologic characteristics of gliomas with EP300::BCOR fusions.
-
Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.
-
Molecular imaging of a fluorescent antibody against epidermal growth factor receptor detects high-grade glioma.
-
Molecular pathogenesis of malignant gliomas.
-
Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA.
-
Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines.
-
Molecularly targeted therapy for malignant glioma.
-
Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
-
Monoclonal antibodies reactive with epitopes restricted to glial fibrillary acidic proteins of several species.
-
Monoclonal antibodies to malignant human gliomas.
-
Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis.
-
Monoclonal antibody therapy of human gliomas: current status and future approaches.
-
Morphologic and molecular genetic aspects of oligodendroglial neoplasms.
-
Morphologic observations of brain tumors in PD4 hamsters induced by four strains of avian sarcoma virus.
-
Multiple-fraction-per-day external beam radiotherapy for adults with supratentorial malignant gliomas.
-
Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas.
-
Mutagen sensitivity and risk of gliomas: a case-control analysis.
-
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.
-
N-acetyl-L-aspartic acid content of human neural tumours and bovine peripheral nervous tissues.
-
NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.
-
Nanoshell-mediated photothermal therapy improves survival in a murine glioma model.
-
Nepsilon-(3-[*I]Iodobenzoyl)-Lys5-Nalpha-maleimido-Gly1-GEEEK ([*I]IB-Mal-D-GEEEK): a radioiodinated prosthetic group containing negatively charged D-glutamates for labeling internalizing monoclonal antibodies.
-
Neuro-oncology: late neurocognitive decline after radiotherapy for low-grade glioma.
-
Neuroradiology case of the day. Multifocal inflammatory leukoencephalopathy due to treatment with 5-fluorouracil and levamisole.
-
Non-additive and epistatic effects of HLA polymorphisms contributing to risk of adult glioma.
-
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
-
O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts.
-
Occurrence of lacto series gangliosides 3'-isoLM1 and 3',6'-isoLD1 in human gliomas in vitro and in vivo.
-
Oncogene amplification in pediatric brain tumors.
-
Oncogenes and anti-oncogenes in human central nervous system tumors.
-
Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.
-
Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas.
-
Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients.
-
PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma.
-
POT1 mutation spectrum in tumour types commonly diagnosed among POT1-associated hereditary cancer syndrome families.
-
PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.
-
PTEN gene mutations are seen in high-grade but not in low-grade gliomas.
-
PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
-
Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.
-
Papillary Glioneuronal Tumor With a Novel GPR37L1-PRKCA Fusion.
-
Parathyroid hormone-related protein regulates glioma-associated oncogene transcriptional activation: lessons learned from bone development and cartilage neoplasia.
-
Partial purification and characterization of a murine glioma-associated antigen defined by syngeneic rat monoclonal antibodies.
-
Partitioned glioma heritability shows subtype-specific enrichment in immune cells.
-
Patterns of the early, gross chromosomal changes in malignant human gliomas.
-
Pericytic-like angiotropism of glioma and melanoma cells.
-
Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging.
-
Permeability of different experimental brain tumor models to horseradish peroxidase.
-
Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.
-
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
-
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
-
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
-
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
-
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
-
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
-
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
-
Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.
-
Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas.
-
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
-
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
-
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.
-
Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).
-
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
-
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
-
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
-
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
-
Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
-
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
-
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.
-
Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure.
-
Phase II study of carboplatin in children with progressive low-grade gliomas.
-
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
-
Phase II study of two-weekly temozolomide in patients with high-grade gliomas.
-
Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).
-
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
-
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
-
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
-
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
-
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
-
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
-
Phase II trial of temozolomide in patients with progressive low-grade glioma.
-
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
-
Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma.
-
Plasmonics-enhanced and optically modulated delivery of gold nanostars into brain tumor.
-
Poliovirus receptor CD155-targeted oncolysis of glioma.
-
Polymorphisms of DNA repair genes and risk of glioma.
-
Polymorphisms of LIG4 and XRCC4 involved in the NHEJ pathway interact to modify risk of glioma.
-
Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts.
-
Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR.
-
Possible association between genetic variants in the H2AFX promoter region and risk of adult glioma in a Chinese Han population.
-
Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors.
-
Potential antiglioma activity of 9-hydroxy-2-N-methylellipticine as determined by pharmacological and human tumor clonogenic cell studies.
-
Predicting grade of cerebral glioma using vascular-space occupancy MR imaging.
-
Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications.
-
Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethyl benzamide.
-
Prevention of glioma induction in rats by simultaneous intracerebral inoculation of avian sarcoma virus plus bacillus Calmette-Guerin cell-wall preparation.
-
Production and characterization of two human glioma xenograft-localizing monoclonal antibodies.
-
Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models.
-
Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers.
-
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.
-
Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas.
-
Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma.
-
Prognostic value of 3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas.
-
Prognostic value of contrast-enhanced magnetic resonance imaging in brainstem gliomas.
-
Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.
-
Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors.
-
Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma.
-
Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors.
-
Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
-
Proteomic and immunologic analyses of brain tumor exosomes.
-
Purification of hexabrachion (tenascin) from cell culture conditioned medium, and separation from a cell adhesion factor.
-
Purine synthesis promotes maintenance of brain tumor initiating cells in glioma.
-
Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma.
-
Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma.
-
Quantitative proton spectroscopy and histology of a canine brain tumor model.
-
Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline.
-
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
-
Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.
-
Radiation-induced malignant gliomas: a current review.
-
Radiogenomics of lower-grade glioma: algorithmically-assessed tumor shape is associated with tumor genomic subtypes and patient outcomes in a multi-institutional study with The Cancer Genome Atlas data.
-
Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.
-
Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.
-
Radioiodination of a monoclonal antibody using N-succinimidyl 5-iodo-3-pyridinecarboxylate.
-
Radioiodination of proteins using N-succinimidyl 4-hydroxy-3-iodobenzoate.
-
Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
-
Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
-
Radiomics Can Distinguish Pediatric Supratentorial Embryonal Tumors, High-Grade Gliomas, and Ependymomas.
-
Radiosensitizing the Vasculature of Primary Brainstem Gliomas Fails to Improve Tumor Response to Radiation Therapy.
-
Radiotherapy management of patients diagnosed with glioma in Victoria (1998-2000): a retrospective cohort study.
-
Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.
-
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
-
Rate of buthionine sulfoximine entry into brain and xenotransplanted human gliomas.
-
Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.
-
Rational for "eight-in-one" chemotherapy.
-
Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better.
-
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.
-
Recurrence of astrocytoma of optic nerve after 48 years.
-
Recurrent isolated sixth nerve palsy in children.
-
Recurrent malignant gliomas.
-
Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas.
-
Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic glioma.
-
Regional blood-to-tissue transport in avian sarcoma virus (ASV)-induced brain tumors.
-
Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: kinetics and implications for diagnosis and therapy.
-
Regional measurements of blood flow in experimental RG-2 rat gliomas.
-
Regional measurements of blood-to-tissue transport in experimental RG-2 rat gliomas.
-
Regulation of MMP-9 (type IV collagenase) production and invasiveness in gliomas by the extracellular signal-regulated kinase and jun amino-terminal kinase signaling cascades.
-
Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
-
Relationship between gene amplification and chromosomal deviations in malignant human gliomas.
-
Relationship of in vitro morphologic and growth characteristics of established human glioma-derived cell lines to their tumorigenicity in athymic nude mice.
-
Releasing the block: setting differentiation free with mutant IDH inhibitors.
-
Relevance for neurobiology and neurooncology of antigens of malignant gliomas as defined by monoclonal antibodies.
-
Resection of gliomas deemed inoperable by neurosurgeons based on preoperative imaging studies.
-
Response assessment criteria for brain metastases: proposal from the RANO group.
-
Response to "the epidemiology of glioma in adults: a 'state of the science' review".
-
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide".
-
Reversible neurotoxicity following hyperfractionated radiation therapy of brain stem glioma.
-
Risk assessment for developing gliomas: a comparison of two cytogenetic approaches.
-
Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics.
-
SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility.
-
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
-
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
-
Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.
-
Sarcoidosis mimicking glioma: case report and review of intracranial sarcoid mass lesions.
-
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
-
Searching for causal relationships of glioma: a phenome-wide Mendelian randomisation study.
-
Second messenger systems in human gliomas.
-
Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation.
-
Selection of a management strategy for pediatric brainstem tumors.
-
Selective modification of antigen-specific T cells by RNA electroporation.
-
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.
-
Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.
-
Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.
-
Serine phosphorylation of glutathione S-transferase P1 (GSTP1) by PKCα enhances GSTP1-dependent cisplatin metabolism and resistance in human glioma cells.
-
Sex-specific gene and pathway modeling of inherited glioma risk.
-
Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21.
-
Single nucleotide polymorphisms of matrix metallopeptidase 3 and risk of gliomas in a Chinese Han population.
-
Single-photon-emission computed tomographic imaging of glioma.
-
Smaller protein, larger therapeutic potential: PPM1D as a new therapeutic target in brainstem glioma.
-
Sodium and water regulation in a patient with cerebral salt wasting.
-
Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells.
-
Somatic mutations in the neurofibromatosis 1 gene in gliomas and primitive neuroectodermal tumours.
-
Some structural aspects of dog brain tumors induced with the Schmidt-Ruppin strain of the Rous sarcoma virus.
-
Spatial distribution of proliferating cells in avian sarcoma virus-induced gliomas.
-
Specific chromosomal abnormalities characterize four established cell lines derived from malignant human gliomas.
-
Specific chromosomal abnormalities in malignant human gliomas.
-
Specific imaging of human brain tumor xenografts utilizing radiolabelled monoclonal antibodies (MAbs).
-
Speckle modulation enables high-resolution wide-field human brain tumor margin detection and in vivo murine neuroimaging.
-
Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.
-
Statin expression in the untreated and SarCNU-exposed human glioma cell line, SK-MG-1.
-
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.
-
Structural alterations of the epidermal growth factor receptor gene in human gliomas.
-
Study of glial fibrillary acidic protein in a human glioma cell line grown in culture and as a solid tumor.
-
Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment.
-
Surface antigenic characteristics of human glial brain tumor cells.
-
Surface antigens of human glioma cells shared with normal adult and fetal brain.
-
Survey of familial glioma and role of germline p16INK4A/p14ARF and p53 mutation.
-
Survival and low-grade glioma: the emergence of genetic information.
-
Susceptibility of inbred Fischer rats to brain tumor induction by Rous sarcoma virus.
-
Synergism between BCNU and irradiation in the treatment of anaplastic gliomas. An in vivo study using the avian sarcoma virus-induced glioma model.
-
Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter.
-
Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG.
-
Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors.
-
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.
-
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.
-
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
-
TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
-
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
-
Tagging SNPs in non-homologous end-joining pathway genes and risk of glioma.
-
Targeted Treatment of Experimental Spinal Cord Glioma With Dual Gene-Engineered Human Neural Stem Cells.
-
Targeted drug delivery to C6 glioma by transferrin-coupled liposomes.
-
Targeted sequencing in chromosome 17q linkage region identifies familial glioma candidates in the Gliogene Consortium.
-
Targeting BRAF-mutant glioma: reflections on the ROAR trial.
-
Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies.
-
Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases.
-
Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia.
-
Targeting cancer stem cells through L1CAM suppresses glioma growth.
-
Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth.
-
Telomere length connects melanoma and glioma predispositions.
-
Telomere maintenance and the etiology of adult glioma.
-
Temozolomide and treatment of malignant glioma.
-
Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats.
-
Temozolomide in children with progressive low-grade glioma.
-
Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis.
-
Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
-
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System.
-
Tenascin expression in human glioma cell lines and normal tissues.
-
Testing for causality between systematically identified risk factors and glioma: a Mendelian randomization study.
-
The Cancer Genome Atlas expression profiles of low-grade gliomas.
-
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
-
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
-
The Effects of Thermal Preconditioning on Oncogenic and Intraspinal Cord Growth Features of Human Glioma Cells.
-
The Epidemiology of Central Nervous System Tumors.
-
The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium.
-
The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.
-
The biology of malignant gliomas--a comprehensive survey.
-
The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.
-
The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion.
-
The current state of immunotherapy for gliomas: an eye toward the future.
-
The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.
-
The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site.
-
The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograft.
-
The effect of an amino acid-lowering diet on the rate of melphalan entry into brain and xenotransplanted glioma.
-
The effects of clinically relevant hyperthermic temperatures on the kinetic binding parameters of a monoclonal antibody.
-
The effects of local hyperthermia on the catabolism of a radioiodinated chimeric monoclonal antibody.
-
The emerging role of anti-angiogenic therapy for malignant glioma.
-
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
-
The epidemiology of glioma in adults: a "state of the science" review.
-
The fine structure of canine gliomas and intracranial sarcomas induced by the Schmidt-Ruppin strain of the Rous sarcoma virus.
-
The fine structure of intracranial neoplasms induced by the inoculation of avian sarcoma virus in neonatal and adult rats.
-
The genetic landscape of gliomas arising after therapeutic radiation.
-
The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly.
-
The induction of intractranial neoplasms by the inoculation of avian sarcoma virus in perinatal and adult rats.
-
The integrated genomic and epigenomic landscape of brainstem glioma.
-
The localisation of radiolabelled murine monoclonal antibody 81C6 and its Fab fragment in human glioma xenografts in athymic mice.
-
The morphologic response of cell lines derived from human gliomas to dibutyryl adenosine 3':5'-cyclic monophosphate.
-
The radiation dose-response relationship in a human glioma xenograft and an evaluation of the influence of glutathione depletion by buthionine sulfoximine.
-
The role of the subependymal plate in glial tumorigenesis.
-
The role of tregs in glioma-mediated immunosuppression: potential target for intervention.
-
The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor.
-
The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience.
-
The use of chemotherapy in patients with gliomas: patterns of care in Victoria from 1998-2000.
-
The use of motor mapping to aid resection of eloquent gliomas.
-
Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts.
-
Therapeutic analysis of in vitro and in vivo brain tumor models.
-
Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model.
-
Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors.
-
Therapeutic profile of the human glioma line D-54 MG in athymic mice.
-
There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy.
-
Thymosin fraction 5 inhibits the proliferation of the rat neuroendocrine MMQ pituitary adenoma and C6 glioma cell lines in vitro.
-
Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.
-
Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate.
-
Tissue is the Issue: Biomarkers of Prognosis and Classification in Adult Gliomas.
-
Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant.
-
Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke.
-
Toward effective immunotherapy for the treatment of malignant brain tumors.
-
Toxin-based targeted therapy for malignant brain tumors.
-
Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma.
-
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
-
Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines.
-
Transient late magnetic resonance imaging changes suggesting progression of brain stem glioma: implications for entry criteria for phase II trials.
-
Treatment of Gliomas: A Changing Landscape.
-
Treatment of WHO Grade 2 and 3 Gliomas With Potentially Favorable Survival: Is Monotherapy Obsolete?
-
Treatment of autochthonous rat brain tumors with fractionated radiotherapy. The effects of graded radiation doses and of combined therapy with BCNU or steroids.
-
Treatment of autochthonous rat brain tumors with steroid plus heparin: a brief report.
-
Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study.
-
Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine, and mithramycin.
-
Treatment of human glioma and medulloblastoma tumor lines in athymic mice with diaziquone and diaziquone-based drug combinations.
-
Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience.
-
Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
-
Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine.
-
Treatment of patients with recurrent primary brain tumors with AZQ.
-
Tumor antigens in astrocytic gliomas.
-
Tumor cell endocytosis imaging facilitates delineation of the glioma-brain interface.
-
Tumor genotype dictates radiosensitization after Atm deletion in primary brainstem glioma models.
-
Tumor hypoxia and prognosis in human gliomas.
-
Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma.
-
Tumor progression and transformation of low-grade glial tumors associated with pregnancy.
-
Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
-
Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing.
-
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
-
Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
-
Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor.
-
Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy.
-
Understanding the Revised Fourth Edition of the World Health Organization Classification of Tumours of the Central Nervous System (2016) for Clinical Decision-making: A Guide for Oncologists Managing Patients with Glioma.
-
Use of quinones in brain-tumor therapy: preliminary results of preclinical laboratory investigations.
-
Vaccine Therapy, Oncolytic Viruses, and Gliomas.
-
Vaccine-based immunotherapeutic approaches to gliomas and beyond.
-
Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas.
-
Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk.
-
Vascular-targeted photothermal therapy of an orthotopic murine glioma model.
-
Virus-cell relationships in dog brain tumors induced with Schmidt-Ruppin Rous sarcoma virus.
-
Viruses and oncogenes in brain tumors.
-
Viruses as therapeutic agents against malignant disease of the central nervous system.
-
Viruses for the treatment of malignant glioma.
-
Viruses in the treatment of brain tumors.
-
Viruses in the treatment of malignant glioma.
-
Visual improvement despite radiologically stable disease after treatment with carboplatin in children with progressive low-grade optic/thalamic gliomas.
-
Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment.
-
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.
-
When tumefactive demyelination is truly a tumor: case report of a radiographic misdiagnosis.
-
Workshop on monoclonal antibodies against gliomas and other neuroectoderm-derived tumors.
-
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.
-
[Benzodiazepine receptors of the mouse glioblastoma cell line: the anomalous effect of gamma-aminobutyric acid on diazepam binding].
-
[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].
-
[New type of specific binding sites for gamma-aminobutyric acid (GABA) found in a mouse glioblastoma].
-
c-Myc is required for maintenance of glioma cancer stem cells.
-
cAMP stimulates transcription of the beta 2-adrenergic receptor gene in response to short-term agonist exposure.
-
cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma.
-
miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways.
-
Keywords of People
-
-
Affronti, Mary Louise,
Clinical Professor in the School of Nursing,
School of Nursing
-
Buckley, Anne Frances,
Assistant Professor of Pathology,
Pathology
-
Craciunescu, Oana,
Professor of Radiation Oncology,
Radiation Oncology
-
Fecci, Peter Edward,
Professor of Neurosurgery,
Biomedical Engineering
-
McLendon, Roger Edwin,
Professor of Pathology,
Pathology
-
Moorman, Patricia Gripka,
Professor Emeritus in Family Medicine and Community Health,
Duke Cancer Institute
-
Ostrom, Quinn,
Assistant Professor in Neurosurgery,
Neurosurgery, Neuro-Oncology
-
Pirozzi, Christopher,
Assistant Professor in Pathology,
Pathology
-
Reitman, Zachary James,
Assistant Professor of Radiation Oncology,
Pathology
-
Sampson, John Howard,
Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine,
Biomedical Engineering
-
Turner, Dennis Alan,
Professor of Neurosurgery,
Biomedical Engineering
-
Yan, Hai,
Adjunct Professor of Pathology,
Pathology